Madecassoside

Madecassoside at a Glance

Madecassoside is the most abundant triterpenoid saponin of gotu kola (Centella asiatica) and — with asiaticoside — one of the two glycoside markers that define the plant’s standardised triterpene fraction (TTFCA / TECA, sold as Madecassol) ^{15Reference 15James JT · 2009Pentacyclic triterpenoids from the medicinal herb, Centella asiatica (L.) UrbanView study →}. Structurally it is the sugar-bearing glycoside of the aglycone madecassic acid; the pair sit alongside the asiaticoside / asiatic acid couple as the four “centelloids” behind gotu kola’s reputation for wound healing and skin repair.

Its preclinical record is broad and fairly consistent — anti-inflammatory, wound- and burn-healing, and organ-protective across rodent and cell models, working mainly by damping NF-κB/MAPK signalling and reinforcing antioxidant defences ^{1,6,7Reference 1Liu M et al. · 2008AnimalMadecassoside isolated from Centella asiatica herbs facilitates burn wound healing in miceView study →Reference 6Wang W et al. · 2018AnimalMadecassoside prevents acute liver failure in LPS/D-GalN-induced mice by inhibiting p38/NF-κB and activating Nrf2/HO-1 signalingView study →Reference 7Cao W et al. · 2010Madecassoside suppresses LPS-induced TNF-alpha production in cardiomyocytes through inhibition of ERK, p38, and NF-kappaB activityView study →}. What complicates the story is delivery: madecassoside is a large, polar saponin that is poorly absorbed by mouth and is largely hydrolysed in the gut to madecassic acid, so much of its oral activity is best read as that of a prodrug plus an unusual gut-level immune effect ^{4,10Reference 4Wang T et al. · 2015Intestinal interleukin-10 mobilization as a contributor to the anti-arthritis effect of orally administered madecassoside: a unique action mode of saponin compounds with poor bioavailabilityView study →Reference 10Leng DD et al. · 2013AnimalIn vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) UrbView study →}.

Human evidence is thin and almost always sits at the whole-extract level — standardised Centella triterpene creams and one topical facial trial — rather than the isolated molecule ^{12,16Reference 12Haftek M et al. · 2008Clinical, biometric and structural evaluation of the long-term effects of a topical treatment with ascorbic acid and madecassoside in photoaged human skinView study →Reference 16Park KS · 2021Pharmacological effects of Centella asiatica on skin diseases: evidence and possible mechanismsView study →}. Toxicity is low: it is a constituent of a long-eaten, long-applied herb, and its poor systemic exposure limits the plausible risk.

Established Uses

The one genuinely real-world use of madecassoside is as a standardised marker and active in topical Centella asiatica preparations. The titrated triterpene extracts TTFCA and TECA (and the branded Madecassol) are reconstituted mixtures of madecassoside, asiaticoside and the two triterpene acids, applied for wound healing, minor burns, scar management and photoaged or irritated skin — the modern “cica” cosmetic category descends directly from this ^{16Reference 16Park KS · 2021Pharmacological effects of Centella asiatica on skin diseases: evidence and possible mechanismsView study →}. In these products madecassoside is one of several defined triterpenes rather than a solo drug, so its established use is extract-level, not isolate-level. A small controlled facial study of a topical combining madecassoside with vitamin C reported improvements in photoaged-skin appearance and structure over months ^{12Reference 12Haftek M et al. · 2008Clinical, biometric and structural evaluation of the long-term effects of a topical treatment with ascorbic acid and madecassoside in photoaged human skinView study →}. Everything below — the anti-arthritic, hepatoprotective, cardioprotective and neuro signals — is considerably less direct and rests on animal and cell work.

Madecassoside as a Prodrug of Madecassic Acid

The single most important fact for interpreting madecassoside’s oral data is what happens to it after swallowing. It is a bulky glycoside with poor passive membrane permeability, and disposition studies in rats show it is extensively hydrolysed — chiefly by gut microbiota — to its aglycone madecassic acid, which is the main form that actually reaches the circulation ^{10,11Reference 10Leng DD et al. · 2013AnimalIn vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) UrbView study →Reference 11Wang T et al. · 2014AnimalA LC-ESI-MS method for the simultaneous determination of madecassoside and its metabolite madecassic acid in rat plasma: comparison pharmacokinetics in normal and collagen-induced arthritic ratsView study →}. In this sense oral madecassoside behaves partly as a prodrug: several of its systemic effects may in fact belong to madecassic acid, the more potent anti-inflammatory of the two ^{10Reference 10Leng DD et al. · 2013AnimalIn vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) UrbView study →}.

That makes one finding especially striking. Despite negligible oral bioavailability, orally-dosed madecassoside still suppresses collagen-induced arthritis in rodents — and the proposed explanation is a local action in the gut wall: madecassoside mobilises intestinal interleukin-10 (IL-10), an anti-inflammatory cytokine, which then tempers systemic joint inflammation ^{4Reference 4Wang T et al. · 2015Intestinal interleukin-10 mobilization as a contributor to the anti-arthritis effect of orally administered madecassoside: a unique action mode of saponin compounds with poor bioavailabilityView study →}. If it holds up, this “poorly-absorbed saponin works from inside the gut” mechanism is a genuinely different way for a molecule to be active than the usual absorb-and-distribute picture — and a useful caution against dismissing saponins purely on bioavailability grounds.

What It's Used For

Madecassoside’s evidence is preclinical-heavy and mechanism-consistent but human-thin. It clusters around a small number of themes — skin/wound repair, inflammation, and protection of the liver, heart and lung — nearly all in rodents or cultured cells, and nearly always for the isolated molecule dosed at concentrations that its own pharmacokinetics make hard to reach from herb intake.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. The scores mix an extract-level topical use that has some human data with otherwise isolate-only preclinical work, so read the per-row basis.

01Wound Healing & Skin RepairPromising52%Mouse burn-healing + component-resolution + standardised-extract topicals with one human trial ^{1,5,12,16Reference 1Liu M et al. · 2008AnimalMadecassoside isolated from Centella asiatica herbs facilitates burn wound healing in miceView study →Reference 5Wu F et al. · 2012Identification of major active ingredients responsible for burn wound healing of Centella asiatica herbsView study →Reference 12Haftek M et al. · 2008Clinical, biometric and structural evaluation of the long-term effects of a topical treatment with ascorbic acid and madecassoside in photoaged human skinView study →Reference 16Park KS · 2021Pharmacological effects of Centella asiatica on skin diseases: evidence and possible mechanismsView study →}

02Anti-Inflammatory / Anti-ArthriticShaky42%Two collagen-induced-arthritis mouse studies + a gut-IL-10 mechanism ^{2,3,4Reference 2Liu M et al. · 2008AnimalAnti-rheumatoid arthritic effect of madecassoside on type II collagen-induced arthritis in miceView study →Reference 3Li H et al. · 2009AnimalMadecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 miceView study →Reference 4Wang T et al. · 2015Intestinal interleukin-10 mobilization as a contributor to the anti-arthritis effect of orally administered madecassoside: a unique action mode of saponin compounds with poor bioavailabilityView study →}

03Organ Protection (Liver, Heart, Lung)Shaky30%Single-model rodent/cell studies: LPS/D-GalN liver failure, cardiac ischaemia, lung fibrosis ^{6,8,9Reference 6Wang W et al. · 2018AnimalMadecassoside prevents acute liver failure in LPS/D-GalN-induced mice by inhibiting p38/NF-κB and activating Nrf2/HO-1 signalingView study →Reference 8Bian GX et al. · 2008AnimalMadecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in ratView study →Reference 9Lu GX et al. · 2014AnimalMadecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice by downregulating collagen depositionView study →}

04NeuroprotectionShaky20%In-vitro neuronal-differentiation screen, as one of several Centella compounds ^{14Reference 14Lin J et al. · 2017Synergistic combinations of five single drugs from Centella asiatica for neuronal differentiationView study →}

Mechanisms

The unifying thread is a damp-the-inflammation, prop-up-antioxidants action via NF-κB/MAPK and Nrf2 — the same machinery whether the tissue is skin, liver, heart or joint. The IL-10 gut route ^{4Reference 4Wang T et al. · 2015Intestinal interleukin-10 mobilization as a contributor to the anti-arthritis effect of orally administered madecassoside: a unique action mode of saponin compounds with poor bioavailabilityView study →} is the outlier worth remembering, because it is how an unabsorbed saponin can still act.

Pharmacokinetics

Madecassoside is a large, polar triterpenoid glycoside, and it behaves like one: poor passive permeability and low oral bioavailability. In-vivo rat disposition studies show it is extensively hydrolysed — largely by intestinal microbiota — to its aglycone madecassic acid, which is the principal form recovered in plasma ^{10Reference 10Leng DD et al. · 2013AnimalIn vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) UrbView study →}; a validated LC-ESI-MS assay quantified both parent and metabolite in rat plasma and found the pharmacokinetics altered in arthritic versus normal animals ^{11Reference 11Wang T et al. · 2014AnimalA LC-ESI-MS method for the simultaneous determination of madecassoside and its metabolite madecassic acid in rat plasma: comparison pharmacokinetics in normal and collagen-induced arthritic ratsView study →}. The practical implications are two-fold: first, many “oral madecassoside” effects are plausibly madecassic-acid effects; second, the in-vitro concentrations used in mechanistic studies are unlikely to be reached from ordinary herb or even extract intake, which is exactly why the gut-local IL-10 mechanism ^{4Reference 4Wang T et al. · 2015Intestinal interleukin-10 mobilization as a contributor to the anti-arthritis effect of orally administered madecassoside: a unique action mode of saponin compounds with poor bioavailabilityView study →} matters. No human pharmacokinetic study of isolated madecassoside has been published; topically, it is one component of standardised extracts whose skin penetration is formulated for, not measured for the isolate.

Clinical Trials

There are no clinical trials of isolated oral madecassoside as a drug. The only human-level evidence is topical and extract-based: a controlled facial study of madecassoside combined with vitamin C in photoaged skin ^{12Reference 12Haftek M et al. · 2008Clinical, biometric and structural evaluation of the long-term effects of a topical treatment with ascorbic acid and madecassoside in photoaged human skinView study →}, and the broader clinical use of standardised Centella triterpene preparations (TTFCA/TECA/Madecassol) in which madecassoside is one of several actives ^{16Reference 16Park KS · 2021Pharmacological effects of Centella asiatica on skin diseases: evidence and possible mechanismsView study →}. Everything mechanistic is preclinical.

Last checked: July 2026.

Isolate vs. Plant Studies

Madecassoside sits at an awkward point on the isolate-vs-plant axis. The mechanistic and animal work is nearly all on the isolated molecule — mouse burn healing ^{1Reference 1Liu M et al. · 2008AnimalMadecassoside isolated from Centella asiatica herbs facilitates burn wound healing in miceView study →}, collagen-induced arthritis ^{2,3Reference 2Liu M et al. · 2008AnimalAnti-rheumatoid arthritic effect of madecassoside on type II collagen-induced arthritis in miceView study →Reference 3Li H et al. · 2009AnimalMadecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 miceView study →}, LPS/D-GalN liver failure ^{6Reference 6Wang W et al. · 2018AnimalMadecassoside prevents acute liver failure in LPS/D-GalN-induced mice by inhibiting p38/NF-κB and activating Nrf2/HO-1 signalingView study →}, cardiac ischaemia ^{8Reference 8Bian GX et al. · 2008AnimalMadecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in ratView study →}, lung fibrosis ^{9Reference 9Lu GX et al. · 2014AnimalMadecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice by downregulating collagen depositionView study →} — which is a strength for attributing effects to this compound. But the human evidence inverts it entirely: people are exposed through whole standardised triterpene extracts (TTFCA/TECA/Madecassol) or a combination topical ^{12,16Reference 12Haftek M et al. · 2008Clinical, biometric and structural evaluation of the long-term effects of a topical treatment with ascorbic acid and madecassoside in photoaged human skinView study →Reference 16Park KS · 2021Pharmacological effects of Centella asiatica on skin diseases: evidence and possible mechanismsView study →}, never the purified isolate, so no human outcome can be pinned to madecassoside alone. Complicating both is the pharmacokinetics: because oral madecassoside is largely converted to madecassic acid before it reaches the blood ^{10Reference 10Leng DD et al. · 2013AnimalIn vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) UrbView study →}, even the clean isolate studies may be reporting, in part, the aglycone’s activity. The most defensible reading is that madecassoside is a well-characterised preclinical actor and a genuine clinical extract-marker, but not an independently proven human medicine.

Prevalence in Nature

Madecassoside is highly characteristic of gotu kola (Centella asiatica, Apiaceae), where it is one of the “centelloid” pentacyclic triterpenoid saponins the plant accumulates in quantity — the group that also includes asiaticoside, brahmoside, thankuniside and the free acids ^{15Reference 15James JT · 2009Pentacyclic triterpenoids from the medicinal herb, Centella asiatica (L.) UrbanView study →}. Within that set it is usually the most abundant marker, reported across surveyed accessions at roughly 0.15–5.3% of the dried herb, though the figure swings widely with genotype, growing conditions, plant part and season, and commercial extracts are standardised far above raw-herb levels ^{15Reference 15James JT · 2009Pentacyclic triterpenoids from the medicinal herb, Centella asiatica (L.) UrbanView study →}. It is largely restricted to Centella and close relatives; it is not a widespread plant metabolite like the simpler triterpenes ursolic acid or oleanolic acid, nor a sterol like beta-sitosterol.

Its Role in Plants

The centelloid saponins are secondary metabolites of Centella, biosynthesised down the pentacyclic-triterpenoid branch of the isoprenoid pathway: the cyclisation of 2,3-oxidosqualene to the ursane skeleton, followed by oxidation to the aglycone (madecassic acid) and glycosylation to the saponin ^{15Reference 15James JT · 2009Pentacyclic triterpenoids from the medicinal herb, Centella asiatica (L.) UrbanView study →}. Like other triterpenoid saponins their presumed ecological function is chemical defence — saponins are surfactant, membrane-disrupting molecules that deter herbivores and microbes. Their production is under jasmonate control: treating Centella cell cultures with methyl jasmonate, a wound/defence signal, up-regulates centelloside biosynthesis, consistent with a defensive role ^{15Reference 15James JT · 2009Pentacyclic triterpenoids from the medicinal herb, Centella asiatica (L.) UrbanView study →}. As always, a defensive plant function does not predict human pharmacology.

Discovery & Synthesis

Madecassoside was first isolated and characterised from Centella asiatica by mid-twentieth-century French phytochemistry — the same body of work that yielded the standardised triterpene extract marketed as Madecassol, and from which the molecule takes its name (from Madécasse, the old French adjective for Madagascar, a Centella source). The exact first-report date is not well documented in the modern literature, and no notable total synthesis is recorded: as a complex glycoside it is obtained by extraction and purification from cultivated gotu kola, not by chemical synthesis. Manufacture today is entirely extractive — madecassoside is separated from the Centella triterpene fraction (chromatographically, or as part of the standardised TTFCA/TECA mixtures) for pharmaceutical and cosmetic use; there is no economic synthetic route.

Patents: not yet researched.

Toxicity & Safety

Madecassoside carries a low flag. It is a major constituent of gotu kola — a plant with a long record of dietary, traditional and topical use — and its poor oral bioavailability ^{10Reference 10Leng DD et al. · 2013AnimalIn vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) UrbView study →} limits systemic exposure from ordinary intake. Rodent efficacy studies at 6–48 mg/kg report benefit without prominent toxicity, and it is a routine ingredient of standardised skin preparations ^{1,16Reference 1Liu M et al. · 2008AnimalMadecassoside isolated from Centella asiatica herbs facilitates burn wound healing in miceView study →Reference 16Park KS · 2021Pharmacological effects of Centella asiatica on skin diseases: evidence and possible mechanismsView study →}. The isolated molecule’s dedicated safety package (repeat-dose, genotoxicity, reproductive) is not well characterised, so the low rating reflects history and low exposure rather than a full toxicology dossier.

Safety at a Glance

✅ Low / no toxicity

• Long-used, low-concern constituent. A major triterpene of edible, topically-applied gotu kola, standard in wound/scar and cosmetic preparations.
• Low systemic exposure. Poorly absorbed by mouth and largely converted to madecassic acid, limiting the dose the body actually sees.
• Isolate safety not fully characterised. No comprehensive repeat-dose, genotoxicity or reproductive dataset for the pure compound; safety judgements borrow from the whole herb.
• Pregnancy/lactation decided at the herb level. Centella asiatica intake in pregnancy is a per-herb decision made on the gotu kola page, not settled by this molecule page.

Dosage

There is no established human dose for isolated madecassoside. Preclinical rodent studies use roughly 6–48 mg/kg orally (e.g. 6–24 mg/kg for burn healing ^{1Reference 1Liu M et al. · 2008AnimalMadecassoside isolated from Centella asiatica herbs facilitates burn wound healing in miceView study →}, 20–40 mg/kg for liver protection ^{6Reference 6Wang W et al. · 2018AnimalMadecassoside prevents acute liver failure in LPS/D-GalN-induced mice by inhibiting p38/NF-κB and activating Nrf2/HO-1 signalingView study →}) — animal research figures, not human recommendations. Real-world human exposure is topical and extract-based: standardised Centella triterpene preparations (TTFCA/TECA/Madecassol) and cosmetic “cica” products, in which madecassoside is one of several defined triterpenes rather than a stand-alone dose. These are doses studied in research and are not a personal recommendation.

References

1. Liu M, Dai Y, Li Y, Luo Y, Huang F, Gong Z, Meng Q (2008). Madecassoside isolated from Centella asiatica herbs facilitates burn wound healing in mice. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/18484522/
2. Liu M, Dai Y, Yao X, Li Y, Luo Y, Xia Y, Gong Z (2008). Anti-rheumatoid arthritic effect of madecassoside on type II collagen-induced arthritis in mice. International Immunopharmacology. https://pubmed.ncbi.nlm.nih.gov/18652917/
3. Li H, Gong X, Zhang L, Zhang Z, Luo F, Zhou Q, Chen J, Wan J (2009). Madecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 mice. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/19135346/
4. Wang T, Wei Z, Dou Y, Yang Y, Leng D, Kong L, Dai Y, Xia Y (2015). Intestinal interleukin-10 mobilization as a contributor to the anti-arthritis effect of orally administered madecassoside: a unique action mode of saponin compounds with poor bioavailability. Biochemical Pharmacology. https://pubmed.ncbi.nlm.nih.gov/25600909/
5. Wu F, Bian D, Xia Y, Gong Z, Tan Q, Chen J, Dai Y (2012). Identification of major active ingredients responsible for burn wound healing of Centella asiatica herbs. Evidence-Based Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/23346217/
6. Wang W, Wu L, Li Q, Zhang Z, Xu L, Lin C, Gao L, Zhao K, Liang F, Zhang Q, Zhou M, Jiang W (2018). Madecassoside prevents acute liver failure in LPS/D-GalN-induced mice by inhibiting p38/NF-κB and activating Nrf2/HO-1 signaling. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/29715757/
7. Cao W, Li XQ, Zhang XN, Hou Y, Zeng AG, Xie YH, Wang SW (2010). Madecassoside suppresses LPS-induced TNF-alpha production in cardiomyocytes through inhibition of ERK, p38, and NF-kappaB activity. International Immunopharmacology. https://pubmed.ncbi.nlm.nih.gov/20381648/
8. Bian GX, Li GG, Yang Y, Liu RT, Ren JP, Wen LQ, Guo SM, Lu QJ (2008). Madecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in rat. Biological & Pharmaceutical Bulletin. https://pubmed.ncbi.nlm.nih.gov/18310910/
9. Lu GX, Bian DF, Ji Y, Guo JM, Wei ZF, Jiang SD, Xia YF, Dai Y (2014). Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice by downregulating collagen deposition. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/24458872/
10. Leng DD, Han WJ, Rui Y, Dai Y, Xia YF (2013). In vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) Urb. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/24091240/
11. Wang T, Leng DD, Gao FF, Jiang CJ, Xia YF, Dai Y (2014). A LC-ESI-MS method for the simultaneous determination of madecassoside and its metabolite madecassic acid in rat plasma: comparison pharmacokinetics in normal and collagen-induced arthritic rats. Chinese Journal of Natural Medicines. https://pubmed.ncbi.nlm.nih.gov/25556066/
12. Haftek M, Mac-Mary S, Le Bitoux MA, Creidi P, Seité S, Rougier A, Humbert P (2008). Clinical, biometric and structural evaluation of the long-term effects of a topical treatment with ascorbic acid and madecassoside in photoaged human skin. Experimental Dermatology. https://pubmed.ncbi.nlm.nih.gov/18503551/
13. An IS, An S, Kang SM, Choe TB, Lee SN, Jang HH, Bae S (2012). Titrated extract of Centella asiatica provides a UVB protective effect by altering microRNA expression profiles in human dermal fibroblasts. International Journal of Molecular Medicine. https://pubmed.ncbi.nlm.nih.gov/22948173/
14. Lin J, Jiang H, Ding X (2017). Synergistic combinations of five single drugs from Centella asiatica for neuronal differentiation. NeuroReport. https://pubmed.ncbi.nlm.nih.gov/27893605/
15. James JT, Dubery IA (2009). Pentacyclic triterpenoids from the medicinal herb, Centella asiatica (L.) Urban. Molecules. https://pubmed.ncbi.nlm.nih.gov/19924039/
16. Park KS (2021). Pharmacological effects of Centella asiatica on skin diseases: evidence and possible mechanisms. Evidence-Based Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/34845411/

View all 16 references▾